Merck KGaA (FRA:MRKC) ROCE %: 9.03% (As of Mar. 2026)


FRA:MRKC Merck KGaA FRA:MRKC
81 GF Score
Price €29.00
GF Value €27.71
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Merck KGaA ROCE %?

Merck KGaA FRA:MRKC +5.07% 81 ROCE % is 9.03% as of Mar. 2026. GuruFocus rates FRA:MRKC with a GF Score™ of 81/100 and a GF Value™ of €27.71 (Fairly Valued). The stock has 9 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Merck KGaA's annualized ROCE % for the quarter that ended in Mar. 2026 was 9.03%.

Merck KGaA  (FRA:MRKC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Merck KGaA ROCE % Related Terms

Merck KGaA ROCE % Historical Data

* Premium members only.

The historical data trend for Merck KGaA's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck KGaA ROCE % Chart

Merck KGaA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.43 12.23 9.66 9.56 8.92

Merck KGaA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.32 9.39 12.51 4.76 9.03
FRA:MRKC
81GF Score
Merck KGaA FRA:MRKC
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck KGaA ROCE % Calculation

Merck KGaA's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=3694/( ( (51596 - 11295) + (51527 - 9042) )/ 2 )
=3694/( (40301+42485)/ 2 )
=3694/41393
=8.92 %

Merck KGaA's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=3892/( ( (51527 - 9042) + (53070 - 9349) )/ 2 )
=3892/( ( 42485 + 43721 )/ 2 )
=3892/43103
=9.03 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 9.03% mean?
Merck KGaA (FRA:MRKC) has a ROCE % of 9.03% as of Mar. 2026.
Is Merck KGaA's ROCE % too high?
Merck KGaA's current ROCE % is 9.03%. The Drug Manufacturers industry median ROCE % is 7.00. Merck KGaA's value of 9.03% is 29.1% above this industry median. Overall, Merck KGaA has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Merck KGaA's ROCE % compare to ZTS and UTHR?
Merck KGaA's ROCE % of 9.03% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. Merck KGaA's value of 9.03% is 29.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Merck KGaA's current ROCE % of 9.03% is 29.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Merck KGaA's current ROCE % is 9.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck KGaA stock overvalued right now?
Based on GuruFocus' analysis, Merck KGaA (FRA:MRKC) is currently considered Fairly Valued. The stock's GF Value™ is €27.71, compared to a current price of €29.00 — trading 4.7% above its estimated fair value. The current ROCE % is 9.03% and 29.1% above the Drug Manufacturers industry median of 7.00. Merck KGaA's overall GF Score™ is 81/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Merck KGaA (FRA:MRKC), the current ROCE % is 9.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck KGaA (FRA:MRKC) Overvalued in 2026?

Based on GuruFocus' analysis, Merck KGaA stock appears to be overvalued. The current stock price of €29.00 is trading 4.7% above its estimated GF Value™ of €27.71. GuruFocus considers Merck KGaA to be Fairly Valued.

Key valuation signals for FRA:MRKC:

  • ROCE %: 9.03%
  • GF Value™: €27.71 vs. price of €29.00 (4.7% above fair value)
  • GF Score™: 81/100 with 9 warning signs
  • Industry Position: 29.1% above the Drug Manufacturers median

No single metric tells the full story. See the FRA:MRKC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Merck KGaA Business Description

Address Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
81GF Score

Get the complete analysis for FRA:MRKC

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€29.00
Price
€27.71
GF Value